METiS Pharmaceuticals made a groundbreaking announcement at the Zhongguancun (Daxing) Cell and Gene Therapy Industrial Park, revealing the world's inaugural AI-driven nanoparticle delivery platform, NanoForge. This innovative platform seamlessly combines quantum chemistry, molecular dynamics simulations, and the company's exclusive high-throughput wet lab screening technologies, forming a closed-loop system that spans from molecular generation to formulation finalization. Leveraging this platform, METiS Pharmaceuticals has introduced three fundamental solutions. Presently, the company possesses an extensive repository of over 10 million lipid structures, 100,000 data points for model training, and has successfully achieved targeted LNP (Lipid Nanoparticle) delivery to eight distinct organs or tissues. Additionally, it has secured more than 100 patents and propelled multiple pipeline projects forward. The NanoForge platform stands out with its four cutting-edge technologies: a vast LNP ionizable lipid library boasting tens of millions of entries, a vertical AI foundational model tailored for nanomaterial innovation, the AI Nanoparticle Delivery Agent (ALAN), and a proprietary integrated dry-wet lab infrastructure. Co-founder and CEO Charles Lai emphasized that this platform is poised to redefine industry standards and has the potential to serve as a catalyst for China's innovative drug research and development. In recent times, nanoparticle delivery systems have transitioned from being a technological hurdle to becoming a pivotal enabling technology, propelling advancements in state-of-the-art therapies.